ATXI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATXI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avenue Therapeutics's book value per share for the quarter that ended in Sep. 2024 was $1.63.
During the past 3 years, the average Book Value Per Share Growth Rate was -69.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Avenue Therapeutics was -48.80% per year. The lowest was -69.10% per year. And the median was -58.20% per year.
Avenue Therapeutics's current price is $0.362. Its book value per share for the quarter that ended in Sep. 2024 was $1.63. Hence, today's PB Ratio of Avenue Therapeutics is 0.22.
During the past 9 years, the highest P/B Ratio of Avenue Therapeutics was 146.25. The lowest was 0.00. And the median was 0.00.
The historical data trend for Avenue Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Book Value per Share | Get a 7-Day Free Trial |
![]() |
453.33 | 157.27 | 181.63 | 61.02 | 4.64 |
Avenue Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Book Value per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-30.42 | 4.64 | 4.81 | 4.00 | 1.63 |
For the Biotechnology subindustry, Avenue Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's PB Ratio falls into.
Avenue Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (1.58 | - | 0.00) | / | 0.34 | |
= | 4.64 |
Avenue Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (2.61 | - | 0.00) | / | 1.60 | |
= | 1.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Avenue Therapeutics (OTCPK:ATXI) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Avenue Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Neil Herskowitz | director | 2109 BROADWAY, SUITE 206, NEW YORK NY 10023 |
Jay D Kranzler | director | 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121 |
Rosenwald Lindsay A Md | director | 375 PARK AVE, NEW YORK NY 10152 |
Fortress Biotech, Inc. | 10 percent owner | 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154 |
Invagen Pharmaceuticals, Inc. | 10 percent owner | SITE B, 7 OSER AVE., HAUPPAUGE NY 11788 |
Alexandra Maclean | officer: Chief Executive Officer | C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014 |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
David Jin | officer: Int. PEO, Int. PFO, and COO | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Joseph Walter Vazzano | officer: Chief Financial Officer | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Curtis Gale Oltmans | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301 |
Lucy Lu | director, officer: President, CEO | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
Elizabeth Garrett Ingram | director | 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362 |
Thomas Gregory Moore | director | C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045 |
Nishant Saxena | director | CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013 |
Jaideep Ashok Gogtay | director | CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-31-2023
By Marketwired • 11-02-2023
By Marketwired • 04-29-2024
By Marketwired • 05-15-2024
By Marketwired • 11-14-2024
By Marketwired • 10-09-2024
By Marketwired • 05-16-2024
By GuruFocus News • 02-15-2025
By Marketwired • 09-03-2024
By sperokesalga sperokesalga • 05-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.